1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Japan Q3 Roundup: Daiichi Emerges As Growth Leader While Others Balance Ups And Downs

 
• By Lisa Takagi

The success of Enhertu led Daiichi Sankyo to raise its annual forecast for the fiscal year ending 31 March, while Eisai is readying for Leqembi’s steady US growth. Meanwhile, Astellas, Chugai and Shionogi balanced growth for some products with declines for others.

Takeda, Astellas, Daiichi Sankyo and Eisai closed their Q3 while Chugai closed its fiscal year 2023.
Takeda, Astellas, Daiichi Sankyo and Eisai reported mixed fiscal Q3 results • Source: Shutterstock

The fiscal quarter ended 31 December was mostly successful for six major Japanese firms, with Daiichi Sankyo Co., Ltd. in particular showing good revenue growth on the back of its blockbuster antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan).

Eisai Co., Ltd. meanwhile expressed hopes for its Alzheimer's disease drug Leqembi (lecanemab), while pushing down R&D costs through its global collaboration with Biogen, Inc., while Astellas Pharma, Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Japan Market Entry: Consortium’s One-Stop Shop To Support Foreign Entrants

 
• By Lisa Takagi

Japanese CDMO Bushu talks about a consortium designed to provide a broad range of development services to smaller foreign firms looking to bring high-need drugs to the Japanese market.

Japan’s Ciconia Seeks Academic Candidates To Hatch In Global Market

 
• By Lisa Takagi

Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.

US-China Tariff War Pressures Pharma’s Complex Supply Chain

 
• By Lisa Takagi

Although pharmaceuticals are exempt from the US reciprocal tariff policy, for now, the escalating global trade war is already posing practical on-the-ground problems for some companies, Scrip hears.

More from Focus On Asia